Harshil Dhruv
0000-0003-2571-6649
Publication & Citation Trends
Most Cited Works
Publications
240 total
Abstract LB237: p300-selective degraders illustrate potent anti-tumor activity in a distinct subset of cancers
Cited by 0
Semantic Scholar
Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degraders.
Cited by 3
Semantic Scholar
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. OA
Cited by 3
Semantic Scholar
151 Exceptional Responders to Base Excision Repair (BER) Inhibition for Recurrent Glioblastoma Display Enrichment for DNA Damage Response Pathways: RNA Sequencing Analysis From a Multicenter Trial OA
Cited by 0
Semantic Scholar
Abstract 2656: The selective IKZF2 molecular glue degrader, PVTX-405, counters Treg immune suppression,shows significant tumor growth delay as single agent and synergistic response with immune checkpoint therapies (ICTs)
Cited by 0
Semantic Scholar
Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication OA
Cited by 1
Semantic Scholar
DNAR-05. EXCEPTIONAL RESPONDERS TO BASE EXCISION REPAIR (BER) INHIBITION FOR RECURRENT GLIOBLASTOMA DISPLAY ENRICHMENT FOR DNA DAMAGE RESPONSE PATHWAYS: RNA SEQUENCING ANALYSIS FROM A MULTICENTER TRIAL OA
Cited by 0
Semantic Scholar
Abstract 4102: Vulnerability signature guided glioblastoma umbrella trial
Cited by 0
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(107)
Radiopharmaceutical Chemistry and Applications
(37)
Cancer, Hypoxia, and Metabolism
(28)
Cancer Mechanisms and Therapy
(25)
Cancer Genomics and Diagnostics
(24)
Frequent Co-Authors
Affiliations
University of North Carolina at Chapel Hill
Utah State University
Translational Genomics Research Institute
Van Andel Institute
Barrow Neurological Institute